Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy

Trial Profile

Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Afatinib (Primary) ; Antineoplastics; Vinorelbine
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms Lux-Breast 3
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Nov 2015 Results published in the Lancet Oncology
    • 07 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 05 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top